Obermatt
See Similar Stocks →

Recursion Pharmaceuticals

NSQ:RXRX · US75629V1044
BiotechnologyMedium

360

20
Profit price16
Cash yield1
Price/Sales53
Price/Book46
Return on Capital24
Cash Return on Capital45
Return on Equity30
Profit margins12
Accruals69
Owner Earnings Margin12
Sales growth36
Profit growth10
Reinvestment19
Price momentum9
Debt load56
Refinancing39
Debt Payback1
Liquidity25
Analyst ratings3
Opinion Changes50
Price Target Upside74
Market mood33
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Recursion Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees599
Websiterecursion.com
ISINUS75629V1044
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Artificial IntelligenceHealth DiagnosticsMachine LearningHematologyChronic DiseasesPredictive AnalyticsNeuroscienceOncologyData and AnalyticsHealth CareScience and EngineeringSoftware

Description

Recursion Pharmaceuticals, Inc. (Recursion) operates as a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. The Recursion Operating System (OS) integrates ‘Real World’ data generated in the company's own…

Analysis

Middle-of-the-road

Recursion Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

All-time high

9

Mar 2026

All-time low

1

Jun 2026

Average rank

5

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
53
—
—
—
Price/Earnings
31
—
—
—
Price/Book
46
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
42
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Recursion Pharmaceuticals with its peers
Sellas Life Sciences
NAQ:SLS
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Candel Therapeutics
NMQ:CADL
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tyra Biosciences
NSQ:TYRA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →